Tenon Medical, Inc. Announces Timing of Fourth Quarter and Full Year 2023 Financial Results

27 Feb 2024
www.biospace.com
Financial Statement
LOS GATOS, CA / ACCESSWIRE / February 27, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced plans to release financial results for the fourth quarter and full year 2023 ended December 31, 2023 after market close on Tuesday, March 12, 2024. The Company will also hold a conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts. Date: Tuesday, March 12, 2024 Time: 4:30 p.m. Eastern time Dial-in: 1-877-407-0792 International Dial-in: 1-201-689-8263 Webcast: TNON Conference Call Please dial in at least 10 minutes before the start of the call to ensure timely participation. An audio playback of the call will be available through March 26, 2024, on Tenon's Investor Relations website at or via telephone replay by dialing 1-844-512-2921(USA) or 1-412-317-6671 (International). The access code will be 13744319. About Tenon Medical, Inc. Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran™ Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022 Tenon is focused on three commercial opportunities with its System in the SI Joint market which includes: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) SI Joint fusion adjunct to a spine fusion construct. For more information, please visit . The Tenon Medical logo, Tenon Medical and Catamaran are registered trademarks of Tenon Medical, Inc. Investor Contact Shannon Devine MZ North America 203-741-8811 tenon@mzgroup.us SOURCE: Tenon Medical, Inc. View the original press release on accesswire.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.